Herbal treatment!

[Igor_Passau]

Boswellia serrata. Boswellia is known to have anti-inflammatory properties. It blocks the chemicals that contribute to inflammation, and has been studied for use in osteoarthritis, rheumatoid arthritis, and IBD. Boswellia has been studied for use in Crohn's disease, ulcerative colitis, and collagenous colitis. In some studies, boswellia has been shown to be effective, but more research is needed before this it can be considered for general use.
http://ibdcrohns.about.com/od/altmedcrohns/p/boswellia.htm

Boswellia's immunomodulatory properties may make it ideal for the treatment of autoimmune and inflammatory diseases.
http://www.greenmedinfo.com/article...-it-ideal-treatment-autoimmune-and-inflammato

Boswellia's anti-inflammatory activity is due in part to its inhibition of prostaglandin E2 synthesis.
http://www.greenmedinfo.com/article...art-its-inhibition-prostaglandin-e2-synthesis

An exclusion diet and nutraceutical therapy has significant therapeutic effects in juvenile Crohn's disease.
http://www.greenmedinfo.com/article...gnificant-therapeutic-effects-juvenile-crohns

Boswellia frereana extracts exhibit anti-inflammatory efficacy in an in vitro model of cartilage degeneration indicating its therapeutic role in treating osteoarthritis.
2009
http://www.greenmedinfo.com/article...matory-efficacy-vitro-model-cartilage-degener


Germinated barley
Germinated barley prolongs remission in patients with ulcerative colitis.
2004
2002


Agaricus brasiliensis или Agaricus blazei Murill
OSLO, Norway—An Agaricus blazei Murill extract (as AndoSan™, from Immunopharma) decreasesvarious inflammatory markers in patients with inflammatory bowel disease (IBD), according to a new study published in the January issue of the Scandinavian Journal of Immunology (2011;73(1):66-75).
Working off the prior findings showing this extract reduced blood cytokines after 12 days of supplementation in subjects with indigestion, researchers from Oslo University Hospital investigated the ability of AndoSan™ to exert similar effects on cytokines in patients with ulcerative colitis (UC) and Crohn's disease. They al so measured fecal calprotectin, a marker for IBD. Eleven patients with Crohn’s and 10 patients with UC consumed 60 ml/day of AndoSan™ for 12 days. Researchers drew blood from patients before and after six hours of lipopolysaccharide (LPS) stimulation ex vivo. They analyzed plasma and fecal calprotectin levels using ELISA and tested 17 cytokines—IL-2, IFN-γ, IL-12 (Th1), IL-4, IL-5, IL-13 (Th2), IL-7, IL-17, IL-1β, IL-6, TNF-α, IL-8, MIP-1β, MCP-1, G-CSF, GM-CSF and IL-10—using multiplex assay.
After 12 days of AndoSan™ supplementation, baseline plasma levels in UC patients were decreased 40 percent for MCP-1; in LPS-stimulated blood levels were reduced by 78 percent for MIP-1β, 44 percent for IL-6, 41 percent for IL-1β, 30 percent for IL-8, 29 percent for G-CSF, 18 percent for MCP-1 and 17 percent for GM-CSF. There were corresponding reductions in Crohn’s: IL-2 (100 percent), IL-17 (55 percent) and IL-8 (29 percent) and for IL-1β (35 percent), MIP-1β (30 percent), MCP-1 (22 percent), IL-8 (18 percent), IL-17 (17 percent) and G-CSF (14 percent), respectively. In addition, fecal calprotectin was reduced in the UC group.
Researchers concluded, “Ingestion of an [Agaricus blazei Murill]-based medicinal mushroom by patients with IBD resulted in interesting anti-inflammatory effects as demonstrated by declined levels of pathogenic cytokines in blood and calprotectin in feces.”
http://www.naturalproductsinsider.com/news/2010/12/agaricus-targets-inflammation-in-ibd.aspx
Effect of an Extract Based on the Medicinal Mushroom Agaricus blazei Murill on Expression of Cytokines and Calprotectin in Patients with Ulcerative Colitis and Crohn’s disease
2010
http://onlinelibrary.wiley.com/doi/1...477.x/abstract

Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)
http://clinicaltrials.gov/ct2/show/NCT01106742

Sophora iaponica
Effects of total alkaloid of Sophora alopecuroides on serum IL-1beta and IL-4 expression in mice with acute ulcerative colitis
http://www.ncbi.nlm.nih.gov/pubmed/20707078?dopt=Abstract
Total alkaloids of Sophora alopecuroides increases the expression of CD4+ CD25+ Tregs and IL-10 in rats with experimental colitis.
http://www.ncbi.nlm.nih.gov/pubmed/20387224

COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE CONTAINING EXTRACTS OF SOPHORA FLAVESCENS

Disclosed is a pharmaceutical composition comprising a Sophora flavescens extract as an active ingredient useful in the treatment of autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, immune mediated or type 1 diabetes mellitus, inflammatory bowel disease, and scleroderma. Also, the Sophora flavescens extract can be used in a food composition which is thus applicable for the treatment of such autoimmune diseases.

http://www.wipo.int/pctdb/en/wo.jsp?WO=2007126259
http://www.wipo.int/pctdb/en/wo.jsp?WO=2007126259&IA=KR2007002074&DISPLAY=DESC

Matrine improves 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice
Matrine is an alkaloid found in kinds of Sophora plants mainly including Sophora flavescens, Sophora alopecuroides and Sophora subprotrata. The aim of the present study was to evaluate therapeutic effects of matrine on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. Two hours following colonic instillation of TNBS, matrine with several doses was given by gastric gavage once daily for 7 days. Comparing with the 0.9% NaCl-treated mice with TNBS-induced colitis, matrine (10 and 20 mg kg−1)-treated mice with TNBS-induced colitis were shown improvements of weight loss, macroscopic score, histological score, and myeloperoxidase (MPO) activity. Moreover, treatments with matrine (10 and 20 mg kg−1) decreased the up-regulated mRNA and protein levels of tumour necrosis factor-α (TNF-α) caused by TNBS. Our findings suggest that matrine improves TNBS-induced colitis in mice and the therapeutic mechanism might be related to the reduction of up-regulated colonic TNF-α production caused by TNBS.

http://www.sciencedirect.com/science...f&searchtype=a

 

[Igor_Passau]

Sophora iaponica help me with my CD!

 

[Igor_Passau]

Frankincense, A Potential Treatment For Arthritis

The answer to treating painful arthritis could lie in an age old herbal remedy - frankincense, according to Cardiff University scientists.

Cardiff scientists have been examining the potential benefits of frankincense to help relieve and alleviate the symptoms of the condition.

"The search for new ways of relieving the symptoms of inflammatory arthritis and osteoarthritis is a long and difficult one," according to Dr Emma Blain, who leads the research with her co-investigators Professor Vic Duance from Cardiff University's School of Biosciences and Dr Ahmed Ali of the Compton Group.

"The South West of England and Wales has a long standing connection with the Somali community who have used extracts of frankincense as a traditional herbal remedy for arthritic conditions.

"What our research has focused on is whether and how these extracts can help relieve the inflammation that causes the pain," she added.

The Cardiff scientists believe they have been able to demonstrate that treatment with an extract of Boswellia frereana - a rare frankincense species - inhibits the production of key inflammatory molecules which helps prevent the breakdown of the cartilage tissue which causes the condition.

Dr Ali adds: "The search for new drugs to alleviate the symptoms of conditions like inflammatory arthritis and osteoarthritis is a priority area for scientists. What our research has managed to achieve is to use innovative chemical extraction techniques to determine the active ingredient in frankincense.

"Having done this we are now able to further characterise the chemical entity and compare its success against other anti-inflammatory drugs used for treating the condition."

The research comes as a result of a seedcorn project, funded by the Severnside Alliance for Translational Research (SARTRE), through the MRC Developmental Pathway Funding Scheme devolved portfolio.

SARTRE is a joint project between Cardiff University and the University of Bristol to combine and accelerate translational research.

Source:
Dr. Corinne Squire
Cardiff University

http://www.medicalnewstoday.com/releases/229265.php

 

[Igor_Passau]

CD and UC ( German)
http://www.univie.ac.at/pharmakognosie/files/protected/Kastner/Teil 5_Magendarmerkrankungen.pdf

Alzgeimer ( ru)
http://ru-patent.info/21/80-84/2184562.html

 

[Dayz]

Thank you for all of this information! the bowelia sounds really interesting I am going to try it.

 

[Ithinkimafigher]

It does sound promising and natural treatments are far more sparkly in my eye =)

 

[Igor_Passau]

Pharmacists Clarify The Anti-Inflammatory Impact Of Frankincense
It was one of the gifts of the Magi - in addition to myrrh and gold they offered frankincense to the newly born baby Jesus. Since the ancient world the aromatic fragrance of burning Boswellia resin has been part of many religious ceremonies and is still used as a means to indicate special festive atmosphere in the church today. But frankincense can do much more: "The resin from the trunk of Boswellia trees contains anti-inflammatory substances," Professor Dr. Oliver Werz of the Friedrich Schiller University Jena (Germany)

says. The chair of Pharmaceutical and Medical Chemistry is convinced that these substances can be very beneficial in therapies against diseases like asthma, rheumatoid arthritis or atopic dermatitis.

However, so far the active substances in frankincense cannot at present be found in drugs in German pharmacies, as the pharmacological impact of frankincense hasn't been thoroughly investigated. "Although Boswellia resin has been used for thousands of years in the Ayurvedic medicine for instance, the clinical studies we have so far are not suffice for a license in Germany and Europe," Professor Werz explains.

But that could change. As part of a mutual project with partners of the University Saarbrücken and a start-up company, Professor Werz and his team examined the curative effect of frankincense. In this project the researchers were able to show where exactly the boswellic acids - which are responsible for the impact of the ingredients of the Boswellia resin - actually interfere in the process of inflammation. "Boswellic acids interact with several different proteins that are part of inflammatory reactions, but most of all with an enzyme which is responsible for the synthesis of prostaglandin E2," Oliver Werz points out. Prostaglandin E2 is one of the mediators of the immune response and plays a decisive role in the process of inflammation, in the development of fever and of pain. "Boswellic acids block this enzyme efficiently and thereby reduce the inflammatory reaction," the Jena pharmacist explains. With this, not only a targeted use in the therapy of inflammatory diseases is conceivable. It can also be expected that boswellic acids have less side effects than today's prevalent anti-inflammatory treatments like diclofenac or indometacin. Their impact is less specific, they can increase the risk of stomach ulcers and can negatively affect renal function.

In their latest study the researchers around Professor Werz additionally compared the resin of different kinds of frankincense in its anti-inflammatory impact. There are more than ten Boswellia species in the world. The most well-known and widely-used one is the Boswellia serrata from Northern and central India. "We were able to show that the resin of the Boswellia papyrifera is ten times more potent," Professor Werz explains a further result of his research. This species mostly occurs in the Northeast of Africa (Ethiopia, Somalia) and on the Arabian Peninsula (Yemen, Oman).

Whether frankincense will become accepted, is indeed not only due to the outcome of the clinical examination which is yet to come. "Boswellic acids exclusively occur in the resin of Boswellia trees and are very difficult to produce synthetically," Werz points out. Therefore these trees are the only source of these promising active ingredients. However Boswellia trees are already an endangered tree species. In many places they are just being used as heating fuel. "Thereby without sustained protection not only plant species are endangered but at the same time medicine loses promising active ingredients," Professor Werz warns.

http://www.medicalnewstoday.com/releases/247622.php

 

[kiny]

Thank you for all of this information! the bowelia sounds really interesting I am going to try it.

The standard dose is around 800 to 1200 (sometimes 1400) mg per day for boswellia serrata. The dose needs to be spread out during the day, since the effect is not long lasting. It's commonly used in Germany for CD. If you can't stomach capsules, the taste of boswellia when mixed with water is very mild, a bit like gember (ginger root), unlike say wormwood or skullcap which have a very strong taste.





http://www.ncbi.nlm.nih.gov/pubmed?term=boswellia%20fibrosis

Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid.
Latella G, Sferra R, Vetuschi A, Zanninelli G, D'Angelo A, Catitti V, Caprilli R, Gaudio E.
Source

Dipartimento di Medicina Interna e Sanità Pubblica, University of L'Aquila, L'Aquila, Italy. [email protected]
Abstract
BACKGROUND:

Currently, no effective preventive measures or medical therapies are available for intestinal fibrosis and, thus, surgery remains the only available strategy in the management of fibrostenotic enteropathies, especially Crohn's disease. The aim of this study was to evaluate the efficacy of a combined therapy of anti-inflammatory Boswellia and antifibrotic Scutellaria extracts on the development of colonic fibrosis in rats.
MATERIALS AND METHODS:

Chronic colonic inflammation-associated fibrosis was induced in rats by intracolonic administration of 2,4,5-trinitrobenzene sulphonic acid (TNBS). Sixty-four healthy male Sprague-Dawley rats were assigned to five groups: 8 controls, 14 TNBS, 14 TNBS orally treated with Boswellia extracts (50 mg kg(-1) day(-1)), 14 TNBS orally treated with Scutellaria extracts (150 mg kg(-1) day(-1)), and 14 TNBS orally treated with both Boswellia (50 mg kg(-1) day(-1)) and Scutellaria extracts (150 mg kg(-1) day(-1)). The colon was removed after 21 days of treatment and assessed by macroscopic, histological, morphometric and immunohistochemical analyses. For immunohistochemical analysis, alpha-smooth muscle actin (alpha-SMA), collagen types I-III, connective tissue growth factor (CTGF), transforming growth factor-beta1 (TGF-beta1), Smad3, Smad7 and CD3 antibodies were used.
RESULTS:

Combined oral administration of Boswellia and Scutellaria significantly improved the course and macroscopic findings of TNBS-induced chronic colitis assessed by disease activity index, colon weight, length, adhesions, strictures, dilatation, thickness, oedema, ulcerations and extension of damage. The histological severity of the colonic fibrosis was also notably improved by the treatment and associated with a significant reduction in the colonic expression of alpha-SMA, collagen I-III, CTGF, TGF-beta1, Smad3, and Smad7.
CONCLUSIONS:

These data demonstrate that the prophylactic administration of anti-inflammatory Boswellia and antifibrotic Scutellaria extracts is effective in preventing colonic fibrosis in TNBS-induced colitis. Their antifibrotic mechanism of action seems to be mediated by the inhibition of TGF-beta1/Smad3 pathway.